These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 6183487)

  • 21. Does use of the Coloscreen Self-Test improve patient compliance with fecal occult blood screening?
    Park SI; Saxe JC; Weesner RE
    Am J Gastroenterol; 1993 Sep; 88(9):1391-4. PubMed ID: 8362837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colorimetric detection of cyanide with a chromogenic oxazine.
    Tomasulo M; Raymo FM
    Org Lett; 2005 Oct; 7(21):4633-6. PubMed ID: 16209497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spectrophotometric assay for protease activity in ionic liquids using chromogenic substrates.
    Nakashima K; Maruyama T; Kamiya N; Goto M
    Anal Biochem; 2008 Mar; 374(2):285-90. PubMed ID: 18078800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spironolactones and glomerular filtration.
    Martínek V; Jirka J; Stríbrná J; Janata V
    Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):277-80. PubMed ID: 6885200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of fecal occult blood and colorectal cancer].
    Herrerías Gutiérrez JM; Caunedo Alvarez JM; Herrerías Esteban JM
    Rev Esp Enferm Dig; 1999 May; 91(5):331-4. PubMed ID: 10362874
    [No Abstract]   [Full Text] [Related]  

  • 26. [Detection of occult blood in the stool].
    Thomas L; Gnauck R
    Internist (Berl); 1981 Jun; 22(6):364-8. PubMed ID: 7019148
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromogenic detection of nerve agent mimics.
    Costero AM; Gil S; Parra M; Mancini PM; Martínez-Máñez R; Sancenón F; Royo S
    Chem Commun (Camb); 2008 Dec; (45):6002-4. PubMed ID: 19030566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Demonstration of occult blood].
    Breuer H
    Dtsch Med Wochenschr; 1972 Nov; 97(47):1838-9. PubMed ID: 4637258
    [No Abstract]   [Full Text] [Related]  

  • 30. [Analytical sensitivity of Krypto-Haem SSW compared with other test tapes for the detection of occult blood in the stool].
    Lampe J; Uhlig K; Jacobasch KH
    Z Med Lab Diagn; 1983; 24(5):271-6. PubMed ID: 6636950
    [No Abstract]   [Full Text] [Related]  

  • 31. [Economic evaluation of colorectal cancer screening with fecal occult blood detection].
    Maté Jiménez J
    Rev Esp Enferm Dig; 2000 Nov; 92(11):764-5. PubMed ID: 11468859
    [No Abstract]   [Full Text] [Related]  

  • 32. Application of the LAL test and the chromogenic substrate test to the detection of endotoxin in human blood products.
    Homma R; Kuratsuka K; Akama K
    Prog Clin Biol Res; 1982; 93():301-17. PubMed ID: 6750644
    [No Abstract]   [Full Text] [Related]  

  • 33. [Characteristics of the ischemic disorders of xenobiotic metabolism in the liver of rats in the early and late stages of recovery].
    Grek OR; Sharapov VI; Litvinov VS; Dolgov AV
    Farmakol Toksikol; 1984; 47(3):114-8. PubMed ID: 6734804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a new chromogenic agar medium for isolation and identification of Group B streptococci.
    Perry JD; Oliver M; Nicholson A; Wright J; Gould FK
    Lett Appl Microbiol; 2006 Dec; 43(6):615-8. PubMed ID: 17083706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative digital image analysis of chromogenic assays for high throughput screening of alpha-amylase mutant libraries.
    Shankar M; Priyadharshini R; Gunasekaran P
    Biotechnol Lett; 2009 Aug; 31(8):1197-201. PubMed ID: 19360387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Detection of occult blood in stool. Methodologic studies of the validity of this test principle with various test systems].
    Herzog P
    Fortschr Med; 1993 Jun; 111(17):303. PubMed ID: 8349273
    [No Abstract]   [Full Text] [Related]  

  • 37. [Early detection of colon carcinomas. Diagnostic series: fecal occult blood].
    Janssen K
    MMW Fortschr Med; 2000 Nov; 142(46):46. PubMed ID: 11132313
    [No Abstract]   [Full Text] [Related]  

  • 38. A randomized controlled trial of a clinic-based support staff intervention to increase the rate of fecal occult blood test ordering.
    Thompson NJ; Boyko EJ; Dominitz JA; Belcher DW; Chesebro BB; Stephens LM; Chapko MK
    Prev Med; 2000 Mar; 30(3):244-51. PubMed ID: 10684748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential properties of the microsomal deamination and hydroxylation reactions.
    Bélanger PM; Lalande M; Atitsé-Gbeassor A
    Res Commun Chem Pathol Pharmacol; 1983 Jun; 40(3):429-41. PubMed ID: 6622818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromogen-substrate assay--as a tool for monitoring a new thrombin inhibitor.
    Rásky K; Pátfalusi M; Vereczkey L
    Acta Pharm Hung; 1993 Jan; 63(1):3-12. PubMed ID: 8452033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.